SelectQuote, Inc. (SLQT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects several challenges: increased costs in the Life Insurance division, dependence on SelectRx amidst reimbursement headwinds, and a decline in Senior segment revenues and EBITDA. Despite revenue growth, the company faces significant short-term financial hurdles, with a negative quarterly EBITDA and declining policy production. The Q&A section reveals uncertainty in reimbursement rate improvements and vague management responses, further dampening sentiment. Without a clear positive catalyst or partnership announcement, these factors collectively suggest a negative stock price reaction in the short term.
Key Financial Performance
Consolidated Revenue $329 million, representing 13% growth year-over-year, driven by strong growth in Healthcare Services.
Senior Revenues $59 million compared to $93 million a year ago, a decline driven by lower policy production due to changes in beneficiary eligibility requirements during the special election period (SEP).
Senior EBITDA Negative $21 million, driven by lower policy production and increased year-over-year investment in new agent hiring in advance of AEP.
Healthcare Services EBITDA Impacted by a $20 million change in drug reimbursement rates with a SelectRx PBM partner, disproportionately affecting the first half of the fiscal year.
Quarterly EBITDA Negative $32 million, below the guided $25 million to $30 million loss range, due to SelectRx margin dynamics.
Senior Policy Production 32% fewer policies written compared to the prior year, attributed to new SEP eligibility rules.
Life Insurance Revenue Expanded nearly 20%, driven by balanced growth in term life and final expense policies.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SelectRx: SelectRx is improving medication adherence and health outcomes. It uses a 30-day packaging model to ensure patients take the correct medications, reducing hospitalizations by 20%. The program also improves adherence rates by 10% within the first year.
Healthcare Services Expansion: The new Kansas facility is ramping up as planned, delivering efficiency gains. However, the segment faced a $20 million impact due to changes in drug reimbursement rates with a PBM partner. Negotiations are ongoing for a longer-term agreement.
Revenue Growth: Consolidated revenue grew 13% to $329 million, driven by Healthcare Services and Life Insurance business.
Senior Segment Performance: Senior revenues declined to $59 million from $93 million due to changes in SEP eligibility requirements. EBITDA loss was $21 million, as expected.
Life Insurance Business: Life Insurance revenue grew nearly 20%, driven by term life and final expense policies. However, increased agent expenses impacted EBITDA.
Medicare Advantage Strategy: Focus on retention and proactive engagement with policyholders to improve recapture rates and retention. The company is leveraging its data-enabled agent-led model to address policyholder needs in a dynamic market.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Senior Revenue Decline: Senior revenues dropped from $93 million to $59 million year-over-year due to changes in beneficiary eligibility requirements during the special election period (SEP). This decline was expected but still represents a significant challenge for the company.
Negative EBITDA in Senior Segment: The Senior segment reported a negative EBITDA of $21 million in the first quarter, driven by lower policy production and increased investment in new agent hiring ahead of the annual enrollment period (AEP).
Healthcare Services EBITDA Impact: A change in drug reimbursement rates with a SelectRx PBM partner negatively impacted Healthcare Services EBITDA by approximately $20 million in the first half of the fiscal year. This issue is expected to disproportionately affect the second quarter.
Uncertainty in Reimbursement Negotiations: The company is actively negotiating a longer-term reimbursement agreement with the PBM partner to stabilize financials. However, the current uncertainty poses a risk to financial predictability.
Policyholder Volatility: The Medicare Advantage market is experiencing elevated policyholder volatility due to shifts in carrier plan benefits and structures. This could lead to increased policy terminations, impacting revenue and retention rates.
Increased Costs in Life Insurance Division: The Life Insurance division experienced higher expenses due to agent reallocation and new agent training, which reduced EBITDA despite revenue growth.
Dependence on SelectRx for Growth: The company’s long-term growth strategy heavily relies on SelectRx and its ability to improve medication adherence and health outcomes. Any disruption in this segment could significantly impact overall performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Healthcare Services EBITDA: First quarter Healthcare Services EBITDA was impacted by a change in drug reimbursement rates with a SelectRx PBM partner. This is a headwind for our 1Q and 2Q Healthcare Services EBITDA margin. The majority of the impact will be recognized in fiscal second quarter. Second quarter adjusted EBITDA for Healthcare Services is expected to be approximately breakeven. Rates per the current contract revert to more normalized levels on January 1, 2026, which underpins the updated fiscal '26 view. The company plans to exit the fiscal year at an annualized EBITDA run rate in the $40 million to $50 million range.
Fiscal 2026 Financial Outlook: The company is not changing its fiscal 2026 financial outlook of $1.65 billion to $1.75 billion in revenue and $120 million to $150 million in adjusted EBITDA. The company remains confident it will be operating cash flow positive during fiscal year 2026.
Medicare Advantage Selling Season (AEP and OEP): For the 2026 AEP and OEP seasons, the company is optimistic about strong performance. It entered the season with excellent retention of tenured agents and had a successful preseason of hiring and training. The company expects tangible benefits from improving policyholder recapture rates and believes its agile sales function and focus on retention will deliver results in a dynamic and disruptive AEP season.
SelectRx and Healthcare Services: The company is actively negotiating a longer-term reimbursement agreement with a PBM partner to create better financial visibility. Despite the near-term reimbursement challenge, the medium- and long-term outlook for expanding operating leverage and improving margins in Healthcare Services remains intact. SelectRx is expected to continue as a meaningful driver of profit and cash flow for the company.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:On SelectRx, you seem to believe the reimbursement headwind is going to be contained in 2025. What gives you comfort that rates will improve next year? And is there a potential that you'll see a similar reimbursement headwind at the end of next year?
A:The CEO explained that a PBM adjusted drug reimbursement rates but remains profitable. They are in constructive discussions to solidify a longer-term agreement and rate structure. The short-term impact is being absorbed in Q1 and Q2, but long-term economics remain attractive, with no change in growth or margin perspective.
Q:Could SelectRx's improvement in MA member retention have a potential positive impact on LTV? And how much data would you need to see before building that into the LTV calculation?
A:The CFO noted that while they observe improved persistency with SelectRx members having Medicare Advantage plans, this is not currently built into lifetime value calculations. The CEO added that the impact is positive but not massive due to a specific cohort of customers.
Q:With regards to helping policyholders understand their plans better to focus more on retention, could you talk a little bit more about what that looks like in practice?
A:The CEO and COO explained that they are using AI, data, and learnings from previous years to improve retention strategies. They focus on targeting the right customers and leveraging their long data history and AI strategies to be cost-effective. They aim to protect their back book of business and assist beneficiaries impacted by plan changes.
Q:Regarding the recent research on social determinants of health, how is it informing your strategy in terms of potential new offerings in the Healthcare Services segment?
A:The CEO and COO discussed using health risk assessments to identify social determinants of health and offer applicable services. They have helped over 50,000 members through SDOH services and are expanding their product offerings. They use AI and consumer data tools to enhance engagement and improve members' overall health.
Q:Can you characterize anything you're seeing in the market during the AEP season different relative to last year?
A:The CEO and COO noted that the AEP season is dynamic, with carriers focusing on profitability, leading to consumer engagement and plan switching. They observed simplification of benefits and a pullback from ancillary benefits, which they believe helps payers and simplifies offerings for customers.
Q:How do you plan to manage the growth or manage the funnel for SelectRx through the busier quarters while focusing on profitability?
A:The COO explained that they are measured in member growth, focusing on profitability and members who need the service most. They are expanding the clinical aspect of the business and have launched the Adherence for All program. The CEO emphasized their confidence in the business's long-term potential despite short-term reimbursement issues.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the question about how much data would be needed to build improved persistency into LTV calculations. They also used vague language when discussing the specifics of their strategy for addressing social determinants of health and the exact impact of AEP market changes on their business.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AEP moment
AEP readiness
AEP season
AEP top
Adherence medication
Advantage medication
Americans SelectQuote
Americans efficiency
CFO result
Danker investor
HMOs SNPs
PBM change
PBM partner
PBM rate
agreement
carrier policyholder
column
compare
confusion
contract
core
fit
health outcome
healthcare
inefficiency
insurance
life
medication adherence
medication risk
pharmacy
policy production
policyholder plan
position
problem
program
rate SelectRx
regimen
reimbursement rate
season Slide
shift
success
view AEP
visibility
SLQT Transcript
SelectQuote, Inc. (SLQT) Q3 2026 Earnings Call Transcript
Unknown5-5
The earnings call reflects mixed signals: stable PBM reimbursement and positive Medicare Advantage outlook are balanced by IRA-induced revenue decline and cautious guidance. The Q&A reveals management confidence in achieving EBITDA targets and operational efficiencies, yet lacks detailed metrics on valuation concerns. Flat membership growth and guidance adjustments suggest limited short-term stock movement. Without market cap data, a neutral prediction is prudent.
SelectQuote, Inc. (SLQT) Q2 2026 Earnings Call Transcript
Positive2-5
The earnings call reveals strong financial performance, with a 12% revenue growth and 26% increase in Healthcare Services revenue. The company maintains a stable fiscal 2026 outlook and anticipates positive cash flow. Despite increased competition in life insurance, the company has strong operational execution and marketing efficiency. The new PBM deal offers stability, and the strategic plan for Medicare Advantage is promising. The Q&A section supports management's confidence, with positive analyst sentiment, suggesting a likely positive stock price movement in the short term.
SelectQuote, Inc. (SLQT) Q1 2026 Earnings Call Transcript
Unknown11-6
The earnings call reflects several challenges: increased costs in the Life Insurance division, dependence on SelectRx amidst reimbursement headwinds, and a decline in Senior segment revenues and EBITDA. Despite revenue growth, the company faces significant short-term financial hurdles, with a negative quarterly EBITDA and declining policy production. The Q&A section reveals uncertainty in reimbursement rate improvements and vague management responses, further dampening sentiment. Without a clear positive catalyst or partnership announcement, these factors collectively suggest a negative stock price reaction in the short term.
SelectQuote, Inc. (SLQT) Q4 2025 Earnings Call Transcript
Unknown8-21
The earnings call presents mixed signals: while there is growth in SelectRx membership and improved EBITDA margins, revenue and Medicare Advantage policies declined. Management's focus on EBITDA and margin expansion over rapid growth, along with AI investments, is positive. However, lower revenue and strategic agent staffing choices raise concerns. Q&A insights do not significantly alter the sentiment, as there are no major catalysts or risks highlighted. Given the lack of market cap data, a neutral stock price movement is predicted.
SLQT Slides
SLQT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
